English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background:  Pushing the surgical limits for initially unresectable colorectal liver metastases (CRLM) are two approaches for sequential liver resection: two-stage hepatectomy (TSH) and associating liver partitioning and portal vein ligation for staged hepatectomy (ALPPS). However, the role of each treatment modality remains ill-defined. The present meta-analysis was designed to compare the safety, efficacy, and oncological benefits between ALPPS and TSH in the management of advanced CRLM.   Methods:  A systematic literature search was conducted from online databases through to February 2020. Single-arm synthesis and cumulative meta-analysis were performed.   Results:  Eight studies were included, providing a total of 409 subjects for analysis (ALPPS:  N  = 161; TSH:  N  = 248). The completions of the second stage of the hepatectomy [98 vs. 78%, odds ratio (OR) 5.75,  p  < 0.001] and R0 resection (66 vs. 37%; OR 4.68;  p  < 0.001) were more frequent in patients receiving ALPPS than in those receiving TSH, and the waiting interval was dramatically shortened in ALPPS (11.6 vs. 45.7 days, weighted mean difference = −35.3 days,  p  < 0.001). Nevertheless, the rate of minor complications was significantly higher in ALPPS (59 vs. 18%, OR 6.5,  p  < 0.001) than in TSH. The two treatments were similar in 90-day mortality (7 vs. 5%,  p  = 0.43), major complications (29 vs. 22%,  p  = 0.08), posthepatectomy liver failure (PHLF; 9 vs. 9%,  p  = 0.3), biliary leakage (11 vs. 14%,  p  = 0.86), length of hospital stay (27.95 vs. 26.88 days,  p  = 0.8), 1-year overall survival (79 vs. 84%,  p  = 0.61), 1-year recurrence (49 vs. 39%,  p  = 0.32), and 1-year disease-free survival (34 vs. 39%,  p  = 0.66). Cumulative meta-analyses indicated chronological stability for the pooled effect sizes of resection rate, 90-day mortality, major complications, and PHLF.   Conclusions:  Compared with TSH, ALPPS for advanced CRLM resulted in superior surgical efficacy with comparable perioperative mortality rate and short-term oncological outcomes, while this was at the cost of increased perioperative minor complications.

frontiers in oncology

Conventional Two-Stage Hepatectomy or Associating Liver Partitioning and Portal Vein Ligation for Staged Hepatectomy for Colorectal Liver Metastases? A Systematic Review and Meta-Analysis